Application of Mitoxantrone Hydrochloride Injection in Transoral Robotic Thyroid Cancer Surgery
Status:
NOT_YET_RECRUITING
Trial end date:
2028-02-01
Target enrollment:
Participant gender:
Summary
Dear Patient, You are invited to participate in a clinical study investigating the Application of Mitoxantrone Hydrochloride Injection for Lymphatic Tracing in Transoral Robotic Thyroid Cancer Surgery. This protocol (Protocol No.: \[To be filled\]) has been reviewed and approved by the Ethics Committee of the Army Center of Specialized Medicine.
I. Background and Objectives 1.1 Disease Burden and Current Treatments 1.1.1 Thyroid Cancer Surgery Thyroid cancer, the most common head and neck malignancy, exhibits rising global incidence. Central compartment lymph nodes are frequent sites of metastasis in papillary thyroid carcinoma (PTC). Transoral endoscopic thyroid surgery offers superior cosmesis versus open surgery. The da Vinci robotic system enhances visualization and instrument maneuverability, overcoming technical limitations of narrow endoscopic operating channels.
1.1.2 Lymphatic Tracers in Thyroid Surgery
Mitoxantrone Hydrochloride Injection for Lymphatic Tracing is China's only approved tracer for thyroid lymphatic mapping. Its high lymphotropic specificity enables:
Lymph node mapping: Forms nanocrystals that permeate lymphatics, staining nodes blue.
Parathyroid negative imaging: Spares parathyroid glands, aiding their identification and reducing postoperative hypocalcemia.
1.2 Study Objectives
Primary: Compare lymph node dissection efficacy and parathyroid protection between:
Intervention: Transoral robotic thyroid lobectomy/total thyroidectomy + central neck dissection (CND) with lymphatic tracing.
Control: Identical surgery without tracing.
Secondary:
1. Compare postoperative parathyroid function between groups.
2. Evaluate tracer sensitivity for metastatic lymph nodes.
1.3 Participating Site and Sample Size Site: Army Center of Specialized Medicine Sample: 114 treatment-nave PTC patients scheduled for transoral robotic surgery (Jan-Dec 2024).
Intervention group (n=57): Mitoxantrone Hydrochloride tracing Control group (n=57): No tracer II. Study Procedures Pre-study: Medical history review, preoperative assessments, and documentation of concomitant medications (30 days postsurgery).
Intervention:
Thyroid exposure Intervention group: Multisite intraglandular tracer injection (0.1 mL/site, depth 0.3 cm; total dose thyroid-dependent).
Both groups: Thyroid lobectomy/total thyroidectomy unilateral/bilateral CND. Intraoperative recording: Thyroid characteristics, tracer dose/injection sites, lymphadenectomy duration.
Pathology:
Total lymph node yield and blue-staining rate. Intraoperative frozen section + final histopathology for metastatic nodes.
Follow-up (Postoperative Day 73):
Physical exam, vital signs, lab tests (CBC, biochemistry, thyroid/parathyroid hormones, electrolytes).
12-lead ECG. Safety monitoring: Adverse events (AEs) tracked until Postoperative Day 14. III. Potential Benefits Improved lymphatic mapping Reduced parathyroid injury, enhanced lymph node clearance, lower AE rates.
Tracer provided at no cost by the sponsor. Note: Efficacy is not guaranteed. Alternative treatments exist. IV. Risks and Inconveniences Potential AEs: Per product labeling and surgical risks. Procedural burdens: Multiple hospital visits and tests. AE management: Immediate medical intervention provided. Compensation per GCP regulations if injury is trial-related.
V. Costs Tracer: NMPA-approved and insurance-covered. Routine care/medications: Patient/insurance responsibility. AE compensation: Sponsor-covered if causally related (per Chinese GCP). VI. Confidentiality
Medical records accessible only to:
Research team Ethics Committee Regulatory authorities No personally identifiable data will be published. VII. Contact Information Ethics Committee: 68757140 Principal Investigator: Dr. Yan Xu / TEL: 68729250 VIII. Voluntary Participation Right to withdraw anytime without penalty. Investigator may discontinue your participation for safety/administrative reasons.
Exit assessments may be required. IX. Decision Process Discuss with your physician/family. Retain this document.
Participant Signature: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Date: \_\_\_\_\_\_\_\_\_
Investigator Signature: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Date: \_\_\_\_\_\_\_\_\_
Phase:
PHASE4
Details
Lead Sponsor:
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University